Interleukin Genetics

Interleukin Genetics was a Waltham, Massachusetts-based personalized health company that developed and marketed proprietary genetic tests for chronic diseases and health-related conditions. Its flagship product, PerioPredict, was a genetic risk panel for periodontal disease and tooth loss, administered by dentists and dental hygienists in approximately one minute during a routine exam. The company also operated under the Inherent Health consumer brand, offering direct-to-consumer genetic tests providing personalized wellness insights. Interleukin Genetics held a CLIA-certified genetics laboratory in Waltham and was publicly traded on OTCQB under the ticker ILIU. In November 2017, the company was acquired by Orig3n, a consumer genetics company, which absorbed its laboratory assets and genetic testing capabilities to accelerate its personalized health platform.